

COVID-19 antibodies – final products have new names

We have now started to launch our COVID-19 antibodies in their final forms. This means replacing clones we have produced *in vivo* with the corresponding clones produced *in vitro*. To separate the two production technologies from one another, we have determined different clone names for the *in vivo* and *in vitro* produced clones. If you have previously ordered any of the *in vivo* products, in the table below you can find the name for the corresponding product produced *in vitro*.

Similarly, we will launch some clones that until now have been available only as R&D samples. The clone name of the commercial product also will change according to the table below.

Note that we will update this list once we launch new clones.

FINAL PRODUCT NAME AND FORMAT <i>In vitro</i> or Recombinant commercial product	PRODUCT REPLACED <i>In vivo</i> or R&D sample
Cat.# 3CV4 Monoclonal anti-SARS-CoV-2 Nucleoprotein	
C518 (<i>in vitro</i>)	NP1518 (<i>in vivo</i>)
C524 (<i>in vitro</i>)	NP1524 (<i>in vivo</i>)
C525 (<i>in vitro</i>)	NP1525 (<i>in vivo</i>)
C527 (<i>in vitro</i>)	NP1527 (<i>in vivo</i>)
C706 (recombinant rabbit MAb)	NP3706 (R&D sample)
C715 (recombinant rabbit MAb)	NP3715 (R&D sample)
Cat.# 3CV2 Monoclonal anti-SARS-CoV-2 Spike	
R107 (<i>in vitro</i>)	RBD1107 (<i>in vivo</i>)

